cyrilzakka/clinical-trials huggingface dataset:
Intermittent Hypoxia and Upper Extremity EMG Recordings in Individuals With Spinal Cord Injury

In this current study, the examiners examine some of the mechanisms of how Acute Intermittent Hypoxia (AIH) effects the upper extremity of survivors of spinal cord injury. This is accomplished both with the use of a load cell to determine elbow strength changes and high density grid electromyography (EMG) to record bicep muscle activations before and after bouts of AIH

It has been shown previously that there is an increase in strength in survivors of spinal cord injury after brief bouts of Acute Intermittent Hypoxia. In this study, participants are fitted with a high density EMG electrode on the biceps brachii, and attached to a load cell at the wrist, they are asked to flex and extend their elbow at various levels of intensity. This is performed before and after the 30 minute session of AIH. The investigators hope to identify specific types of motor units of the upper extremity of survivors of spinal cord injury after AIH to help further our understanding of what mechanisms may be causing the known increase in muscle strength post AIH

Eligibility Criteria:
Inclusion Criteria:

* History of Spinal Cord Injury from C3-T4
* Non-progressive spinal cord injury
* More than 6 months since initial Spinal Cord injury
* Ability to understand and willingness to sign written informed consent

Exclusion Criteria:

* Presence of any of the following medical conditions: Congestive heart failure, arrhythmia, uncontrolled high blood pressure, uncontrolled diabetes mellitus, COPD/emphysema and severe asthma
* Persons with known coronary artery disease, a history of myocardial infarction, or known carotid or intracerebral artery stenosis
* Medical clearance will be required if participant is taking any other investigational agents
* Women who are pregnant or nursing
* Individuals with tracheostomy
* Cannot pursue other research studies which may interfere
* Unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Prisoners
Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis

The investigators study the efficacy and safety of tacrolimus in the treatment of membranous nephritis secondary to systemic lupus erythematosus.

Glomerulonephritis is one of the major disease manifestations of systemic lupus erythematosus (SLE). The treatment of membranous (type V) lupus nephritis, a subset that carries a high morbidity, remains unsatisfactory. Recent studies suggest that immunosuppressive therapy targeted against the calcineurin pathway of T-helper cells, for example, tacrolimus, may be effective in the treatment of primary membranous nephropathy. The investigators plan to conduct an open-label single-arm study of the efficacy and safety of tacrolimus in the treatment of membranous nephropathy secondary to SLE. Twenty patients with biopsy-proven membranous nephropathy secondary to SLE will be recruited. They will be treated with oral prednisolone and tacrolimus for 6 months, followed by 6 months of maintenance steroids alone. Proteinuria, renal function, clinical and serologic lupus activity will be monitored. Complete remission is defined as 24-hour urinary protein excretion to less than 0.5 gm/day. This study will explore the potential role of tacrolimus in the treatment of membranous lupus nephritis, which is usually resistant to conventional therapy.

Eligibility Criteria:
Inclusion Criteria:

* Fulfill the revised American College of Rheumatology criteria for SLE
* Have biopsy-proven membranous nephropathy secondary to SLE
* Nephrotic syndrome with proteinuria (\> 3 g/day) and serum albumin \< 30 g/dl, with or without active urinary sediments despite steroid therapy (with or without cytotoxic agents)
* Age over 18 with informed consent
* Female patients of child-bearing age and male patients who agree to maintain effective birth control practice during the study

Exclusion Criteria:

* Patient with abnormal liver function tests
* Patient with hepatitis B surface antigen or who is hepatitis C antibody positive
* Patient who is diabetic
* Patient who is receiving non-steroidal anti-inflammatory drugs (NSAIDs) or other agents known to influence urinary protein excretion
* Patient is allergic or intolerant to macrolide antibiotics or tacrolimus
Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations

the pharmacokinetics of sildenafil following single doses of sildenafil CT administered with and without water is similar relative to the conventional oral tablet of sildenafil administered with water.


Eligibility Criteria:
Inclusion Criteria:

* Only healthy male volunteers in the 18-40 age range will be included.
* At the selection visit allowed normal range for vital signs will be: Blood pressure (with the subject sitting down) 90-130mm Hg systolic and 60-90
* The volunteers' health condition will be determined from their complete clinical history by doctors at the clinical research site and lab test results by certified clinical laboratories mm Hg diastolic, heart rate 55-100 bpm , respiratory rate 14-20 respirations per minute.

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at Screening.
* Treatment with a PDE-5 inhibitor within the 4 days preceding the first dose of study medication
* History of hypersensitivity to sildenafil citrate or any components of its formulations
Randomized Trial Of Achieving Healthy Lifestyles In Psych Rehabilitation

This study will determine whether a behavioral weight loss intervention including dietary counseling and exercise is effective in helping people with serious mental illnesses lose weight.

The objective of this study is to perform a randomized clinical trial (ACHIEVE) to definitively test the efficacy of an innovative, practical intervention to accomplish weight loss in overweight and obese persons with SMI. This multi-site trial will enroll consumers with SMI who attend ten psychiatric rehabilitation centers in Maryland and randomize participants to the ACHIEVE intervention or control. Intervention participants will receive group and individual weight loss counseling sessions and group physical activity classes. Co-primary outcomes will be change in weight from baseline to 6 and 18 months.

Eligibility Criteria:
Age 18 and older;

* Overweight, defined by Body Mass Index at least 25.0 kg/m2;
* Able and willing to give informed consent and participate in the intervention;
* On the same psychiatric medications within the 30 days before baseline weight (dose changes allowed;)
* Able to attend at least 2 intervention sessions per week during initial 6-month phase;

Exclusion criteria

* Contraindication to weight loss

  * Receiving active cancer treatment (radiation/chemotherapy)
  * Liver failure
  * History of anorexia nervosa;
* Cardiovascular event (unstable angina, myocardial infarction) within previous 6 months;
* Prior or planned bariatric surgery;

Use of prescription weight loss medication or over-the-counter orlistat within 3 months

if participant does not agree to stop taking it;

* Twenty pound or greater weight loss in 3 months prior to baseline, as documented by staff measurement;
* Inability to walk to participate in exercise class;
* Pregnant or planning a pregnancy during study period. Nursing mothers would need approval from physician;
* Alcohol or substance use disorder either: 1) active and determined to be incompatible with participation in the intervention through discussion with program staff; or 2) new abstinence from alcohol or substance use disorder in past 30 days;
* Planning to leave rehabilitation center within 6 months or move out of geographic area within 18 months;
* Investigator judgment (e.g., for concerns over safety, adherence or follow-up);
* Weight greater than 400 pounds.
Factors Associated With Advanced HIV and Poor Nutrition Among People Living With HIV

Aim of the work:

1. To determine the frequency of advanced HIV among PLWH in Assiut University Hospital.
2. To assess the nutritional patterns and frequency of poor nutrition among PLWH.
3. To evaluate factors associated with advanced HIV disease and poor nutrition among PLWH.

Human immunodeficiency virus (HIV) is an RNA virus that attacks the human body's immune system, which results, in advanced cases, in expression of opportunistic infections (1). HIV infection represents a global public health burden (2, 3). In Egypt, in 2022, about 34,000 people (\<0.1%) were positive for HIV (4). There is 25-30% annual increase of newly confirmed HIV cases in Egypt over the last 10 years (5).

The WHO defines advanced HIV disease as having CD4+ T-cell count \<200 cell/mm3 or having an acquired immune deficiency syndrome (AIDS)-related infection (stage 3 or 4 of HIV infection) regardless of the CD4+ T-cell count (1).

The WHO reported, in 2022, that 630,000 people living with HIV (PLWH) died from AIDS-related diseases worldwide (which is 51% fewer than those in 2010) (2, 3, 6). In Egypt, the AIDS-related deaths increased from \<100 PLWH in 1990 to \<1000 PLWH in 2021 (5).

PLWH are usually malnourished due to opportunistic infections, poor food intake, changes in metabolic activity or chronic illnesses. Malnutrition leads to more impairment of the immune system and further disease progression (7).

According to 2023 Global Hunger index, Egypt is at a moderate level of food insecurity, ranking 57 out of 125 countries. 14.4% of the Egyptian population are food insecure (8).

In Egypt, there is lack of data about the frequency of advanced HIV disease and the nutritional status among PLWH and associated factors. Monitoring these factors could help in early treatment of HIV infection, prevention of further virus transmission and enhancement of the nutritional pattern among PLWH.

Eligibility Criteria:
Inclusion Criteria:

* (1) Newly diagnosed people living with HIV (PLWH), (2) Patients previously diagnosed with HIV but non-compliant to treatment.

Exclusion Criteria:

* (1) PLWH compliant on ART, (2) PLWH who refuse to participate in the study
The BEACON Registry: Best Expert Agreement for Care of Occult Myocardial Infarction (MI) Nationally

The purpose of this registry is to assess and improve the process of care and health outcomes of patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin. The study will identify which methods facilitate the diagnosis and risk stratification of ST elevation myocardial infarction (STEMI) or non STEMI, including patients with occult myocardial infarction (MI), and result in a shorter time to definitive diagnosis and treatment.

The BEACON Registry is a multi-center data collection and follow-up registry. Participating Sites will collect information on patients presenting to the Emergency Department (ED) with chest pain. The purpose of the BEACON Registry is to evaluate the impact of new technologies, practice patterns and initiatives on patient time to diagnosis, patient time to treatment, patient survival and overall economics.

Eligibility Criteria:
Inclusion Criteria:

* Patients presenting with chest pain suspected to be of cardiac origin.

Exclusion Criteria:

* None
Validation of a Diagnostic Self-assessment Scale Non-motor Fluctuations at the Parkinson's Patient

The objective of this study is to validate a diagnostic tool severity of these common non-motor manifestations, disturbing and little recognized as a self-questionnaire. This assessment tool used on different subgroups of patients (free from any treatment at an early stage of the disease and the stage of motor complications) will better understand the natural history of the non-motor fluctuations (FNM)


Eligibility Criteria:
Inclusion Criteria:

Patient aged 30 or over Patient having an Parkinson's disease Patient hospitalized in one of the clinical sites participating in the project Patient have agreed to participate in the study subject that masters the French language and able to fulfill the self-questionnaire.

Exclusion Criteria:

Patient aged under 30 Patient can not answer the self-administered questionnaire Patient has not agreed to participate in the study.
Placebo Controlled Efficacy Evaluation of the Hydrolyzed Collagen Peptide In Adult Females

The aim of this study is to evaluate the contribution of hydrolized collagen products to elasticity, hydration and roughness of the skin of female volunteers. Safety and tolerability of the product is the other objective of this placebo-controlled, randomized study.


Eligibility Criteria:
Inclusion Criteria:

* Female volunteers aged between 35 and 60 years,
* Volunteers who have normal physical examination at screening visit,
* Volunteers who have ability to communicate adequately with the investigator and in agreement to comply with the study requirements,
* Volunteers who have normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 100 bpm at least after 5 minutes of rest,
* Volunteers who have understanding of the study and agreement to give a written informed consent.

Exclusion Criteria:

* Who have atopic constitution or asthma and/or known allergy for biosynthetic collagen products and/or other any of the excipients of the product.
* Who have hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
* Who have the use of oral retinoids or oral steroids in the 6 months prior to initiation of the study.
* Who have the use of topical retinoids, anti-wrinkle cosmetic products including retinol and/or AHA, or moisture-rich cosmetic products within the 3 months prior to initiation of the study.
* Who use skincare therapy using lasers or peeling within the 3 months prior to initiation of the study.
* Who have current participation in another clinical study, or participation in any type of dermatology study within 3 months.
* Who have any history or presence of clinical relevance of cardiovascular, neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphiria.
* Who have the presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
* Who had undergone, or planned to undergo, pregnancy or breastfeeding.
* Who have current intake of contraceptives, female hormones, obesity drugs, absorption inhibitors, antidepressants, or appetite suppressants.
* Who are suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgment.
* Who have history of drug abuse.
* Who have relationship to the investigator.
* Who are not suitable to any of inclusion criteria.
* Who have history of difficulty of swallowing.
* Who are on a special diet due to any reason, or, have gained or lost 5% of baseline weight.
Oral Ulcer Prevalence: Hospital-based Cross-sectional Study

Oral Ulcers have serious effect on patients' lives. Due to absence of any information about its prevalence, risk factors and effect on patients' lives, this study has been held. The investigators recruited patients from the outpatient dental clinic of the faculty of oral and dental medicine, Cairo University, screened them clinically for oral ulcers. All patients filled questionnaires about the risk factors of oral ulcers. Furthermore, oral ulcer patients filled questionnaires about their Quality of life, previous treatments used, previous physicians visited and their Quality of life after using previous treatments.

Oral ulcers form a category of oral lesions that is frequently encountered by the dentist. It influences the patients' lives greatly. In a first step to reducing the disease burdens on patients, basic data about the disease distribution and possible risk factors should be gathered through epidemiological studies.

This cross-sectional study consisted of a convenience sample of 605 dental patients recruited in the time from August to October 2015. The study was held in the outpatient oral diagnosis clinic, Faculty of Oral and Dental Medicine, Cairo University, Egypt; which is an open public facility, a tertiary healthcare and a referral center.

For each participant, the study details were explained and the consent was received. Then, medical history was taken, comprehensive oral examination was done, history of any detected oral ulcer was investigated. The questionnaire was filled through a face-to-face interview.

Comprehensive oral examination was held on a dental unit using the light of the unit, mirror and probe.

After full examination and questionnaire filling, the oral ulcer patients were educated about their oral problem and their ulcers were managed. If the patient's condition needed further investigations or management, referral was done to the appropriate department of the faculty.

The Questionnaire included a section for demographic information of age, sex, social and educational levels of the patient. It also included questions about medical condition, habits of trauma, smoking and its frequency.

After examination, if an ulcer was detected, a part of the questionnaire was filled describing the ulcer: site, size, number, shape, distribution, depth, edges, floor, margins, induration and regional lymph node status. Also, the (OHIP-14) questionnaire was filled to assess the effect of the ulcer on the patient's quality of life.

The questionnaire included questions about previous treatments used by the patients, the patients' assessment of their effect and the source of the patients' information about these therapies.

The patients was also asked about their previous experiences with dentists or physicians seeked to treat these ulcers.

Eligibility Criteria:
Inclusion Criteria:

* Subjects whose age was above 15 years old.

Exclusion Criteria:

* Subjects having problem in opening their mouth (due to non-oral ulcer cause) or undergoing intermaxillary fixation where oral examination was not possible.
Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome

Efficacy of the use of GnRH antagonist in treatment of those who develop early-onset severe ovarian hyperstimulation syndrome and had cancelled embryo transfer


Eligibility Criteria:
Inclusion Criteria:

* Women who develop early-onset severe ovarian hyperstimulation syndrome after controlled ovarian stimulation using long GnRH agonist protocol and hCG for triggering ovulation.

Exclusion Criteria:

* Women on short or antagonist protocols.
* Women who received GnRH agonist for triggering ovulation.
* Women who had embryo transfer.
Bupivacaine Versus Bupivacaine Plus Lidocaine in Infraclavicular Block

In this study, the investigators will compare two different anesthetic solutions in the infraclavicular block in patients having forearm, wrist, and hand surgery. The solutions will be bupivacaine 0.5% versus bupivacaine 0.25% plus lidocaine 1%, both associated with epinephrine 5 mcg/ml and dexamethasone 4 mg.

The main objective of this investigation is to demonstrate that using higher concentrations of bupivacaine alone results in a significant block duration increase compared with the mixture of bupivacaine and lidocaine.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 80 years
* American Society of Anesthesiologists classification 1-3
* Surgery of the forearm, wrist, and hand
* Weight ≥ 80 kilograms

Exclusion Criteria:

* Adults who are unable to give their consent
* Infection in the injection site (infraclavicular region)
* Pre-existing neuropathy (assessed by history and physical examination)
* Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work, i.e., platelets ≤ 100, International Normalized Ratio ≥ 1.4)
* Renal failure (assessed by history and physical examination and if deemed clinically necessary, by blood work, i.e., creatinine ≥ 1.2)
* Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work, i.e., transaminases ≥ 100)
* Allergy to local anesthetics (LAs)
* Pregnancy or breastfeeding
* Prior surgery in the infraclavicular region
* Chronic pain syndromes requiring opioid intake at home
Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy

Aquatic intervention had been applied in children with neuromotor impairment for years, yet there has been little progress toward objective identifications of therapy goals, interventions, and outcomes. Thus, we attempt to design aquatic intervention activity for children with cerebral palsy to evaluate the effect of hydrotherapy.

Purpose:

To evaluate the effects of pediatric aquatic therapy on motor performance, daily activity and social participation in children with spastic cerebral palsy.

Method:

The study enrolled 27 children with spastic cerebral palsy aged from 4 to 12 years old.These children were dived into two groups: traditional rehabilitation therapy (control group), and hospital based pediatric aquatic therapy program. We evaluate the motor performance, daily activity and social participation before and after the intervention and compared the difference in improvement between groups. The measurements include modified Ashworth score, Gross Motor Function Measure (GMFM -66), Vineland Adaptive Behavior Scale (VABS) , and Cerebral Palsy Quality of Life Questionnaire for Children (CPQOL).

Expect effect:

We suppose pediatric aquatic therapy in spastic cerebral palsy children could improve motor function and daily activity.Children could improve self-esteem and we hypothesize this could improve social participation.

* We conducted a well-designed study to investigate the effectiveness of PAT on motor function, activities of daily living (ADL),and health related quality of life(HRQOL) perspectives for children with CP.
* A convenience sample of 27 children was recruited for the study from the outpatient clinics of the Department of Physical Medicine and Rehabilitation of two tertiary hospitals: Chang Gung Memorial Hospital and Taipei Veterans General Hospital.
* The study was designed as a single blinded, prospective, case control study.
* The pediatric aquatic therapy group got more improvementon motor performance measured by GMFM-66.

Eligibility Criteria:
Inclusion Criteria:

1. Children diagnosed as cerebral palsy, spastic type
2. Gross Motor Functional Classification (GMFCS) level II-IV
3. Age: 4-12 y/o
4. Informed consent by parents
5. Modified Ashworth score 2 or3
6. If participant history of epilepsy ,well controlled by medication

Exclusion Criteria:

1. History of psychiatric diseases
2. Poor controlled epilepsy
3. Received botox injection or surgery in recent three months
4. Children diagnosed as attention deficit hyperactivity disorder(ADHD) or autism
5. Severe mental retardation
6. Active infection (Body temperature \> 100°F)
7. Communication problems
8. Bowel incontinence
9. Bladder incontinence
10. Severe cardiovascular disease
11. Infectious skin conditions and open wound
12. Nasogastric tubes or gastrostomy tubes
13. Colostomy ,urostomy or ileostomy bags
14. Acute orthopedic injury with pain and instability
15. Diabetes
16. Chlorine sensitivity
17. Latex allergies
18. Tracheostomy